The study was co-led by Kasiani Myers of the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center, working alongside 26 fellow researchers from the International SDS Research Consortium. Their central conclusion is stark: performing transplants in patients aged 14 and younger, shortly after detecting warning signs such as clones of mutated bone marrow cells or progressive dysplastic changes, appears to dramatically improve two-year survival compared with delaying intervention until myelodysplastic syndrome or acute myeloid leukemia has already taken hold. For patients with this rare condition, the researchers argue, waiting until malignancies are diagnosed may simply be too late.

Shwachman-Diamond syndrome is caused by mutations in the SBDS gene, inherited in an autosomal recessive pattern, meaning both parents must pass on a mutated copy for a child to be affected. The disorder disrupts normal development of the pancreas, skeletal system, liver, and central nervous system, but its most lethal consequence is the transformation of bone marrow into myelodysplastic syndrome or acute myeloid leukemia. The condition was first described in 1964 by Harry Shwachman and Louis Diamond, two physicians who recognized a distinctive pattern of pancreatic insufficiency and bone marrow failure in young patients. Because standard prenatal and newborn screening panels do not test for the syndrome, diagnosis typically occurs during infancy through physical examinations and blood counts that reveal abnormally low levels of circulating cells.

The clinical picture in early childhood is often dominated by digestive and growth problems rather than malignancy. Infants and toddlers with the syndrome frequently struggle with feeding difficulties, failure to thrive, and recurrent infections driven by neutropenia, a shortage of infection-fighting white blood cells. Many lack the pancreatic enzymes needed to digest food properly, requiring lifelong enzyme replacement therapy. Skeletal abnormalities such as scoliosis and delayed tooth development are common, and specialty dental care becomes a recurring part of medical management. Over time, however, the marrow itself becomes increasingly unstable, and the risk of leukemic transformation climbs steadily with age.

To quantify that risk with unprecedented precision, the international team pooled data from 847 cases spanning patients from infancy to beyond age 50, creating the largest known collection of Shwachman-Diamond syndrome outcomes in existence. The numbers they uncovered are sobering. While the incidence of potentially lethal malignancies was as low as 2 percent among 5-year-olds, the cumulative risks of myelodysplastic syndrome, acute myeloid leukemia, and bone marrow failure approached 78 percent by age 50. In other words, nearly four out of five people born with the syndrome will face a life-threatening hematologic crisis by midlife if current surveillance and treatment patterns remain unchanged.

The survival data surrounding early transplantation are the study’s most practice-changing finding. Among 24 high-risk patients who underwent hematopoietic cell transplantation before a malignancy was diagnosed, nearly 82 percent were alive two years after the procedure. By contrast, two-year survival dropped to 55 percent when the transplant was performed after myelodysplastic syndrome had already been identified, and fell further to 36 percent once acute myeloid leukemia had emerged. The gradient is unambiguous: the earlier the intervention relative to malignant transformation, the better the outcome. The co-authors state that these data support surveillance and early transplantation for patients who develop high-risk features, preempting malignancy rather than reacting to it.

The concept of clonal evolution is central to understanding why timing matters so much. In Shwachman-Diamond syndrome, the bone marrow gradually accumulates genetically distinct populations of cells, some of which carry mutations that confer a growth advantage and predispose toward leukemia. When clinicians detect these mutated clones or observe progressive dysplastic changes under the microscope, they are essentially witnessing the earliest molecular steps of a trajectory toward cancer. The new study suggests that this window, before frank malignancy appears, represents the optimal moment for replacing the compromised marrow with healthy donor stem cells through transplantation.

Current clinical practice has generally taken a more conservative approach, with physicians tending to defer transplantation until patients develop myelodysplastic syndrome or acute myeloid leukemia, conditions that are far more dangerous and harder to treat. The reasoning behind that caution has been understandable, since stem cell transplants carry significant risks of their own, including graft-versus-host disease, infection, and organ toxicity. But the new survival figures suggest that this conservatism may be misplaced for patients with clear high-risk biomarkers. The rising global use of genetic screening tests may help reveal more children born with the syndrome, potentially allowing earlier-stage treatment and wider awareness of the testing needed to detect high-risk biomarkers before transformation occurs.

Significant barriers remain, however, and the researchers are careful not to overstate what the data can support. Stem cell transplants are expensive procedures that pose real risks of complications, potentially limiting access for young people in low-resource regions where the syndrome may be underdiagnosed or misdiagnosed. Advocates believe the true number of affected individuals in the United States could be as high as 3,000, far exceeding the roughly 400 patients currently identified, because many cases go unrecognized. More research is needed to determine the ideal age and risk factors for moving forward with transplantation, and whether alternative therapies can be developed that would spare patients the risks of the procedure itself.

Funding for the project came from multiple sources, including the National Institutes of Health, a Cancer Research UK Discovery Award, the UK Medical Research Council, the Rosetrees Trust, and a European Cooperation in Science and Technology Action grant. The study’s conflict-of-interest disclosures note that several co-authors serve as consultants for Athernal Bio and that Myers has received research support from Elixirgen Therapeutics and Incyte. The publication arrives at a moment when the International SDS Research Consortium hopes its findings will prompt clinicians worldwide to reconsider when to intervene, replacing a reactive posture toward malignancy with a proactive one grounded in molecular surveillance. For families navigating a condition that has offered few decisive treatment options, the study provides something rare and valuable: a clear, evidence-based signal that acting early, before cancer develops, may be the single most important choice available.

Subject of Research: Timing of hematopoietic cell transplantation for improving survival in Shwachman-Diamond syndrome

Article Title: Earlier HCT improves survival for youth with Shwachman-Diamond Syndrome

Article References: Earlier HCT improves survival for youth with Shwachman-Diamond Syndrome. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: Shwachman-Diamond syndrome, hematopoietic cell transplantation, bone marrow failure, myelodysplastic syndrome, acute myeloid leukemia, SBDS gene, clonal evolution, Cincinnati Children's Hospital, New England Journal of Medicine, rare genetic disorder, stem cell transplant, leukemia risk

The durability of those responses is as consequential as their depth. Multiple myeloma is a cancer of plasma cells, the antibody-producing arm of the immune system, and it is notorious for relapsing after initially effective treatment. The anito-cel trial therefore tracked patients well beyond the initial response window. More than half of the participants remained progression-free two years after receiving the therapy, and 65 percent were still alive three years out. In a population whose disease had already resisted multiple prior lines of therapy, those figures suggest that a single treatment can reset the course of the disease for a meaningful fraction of patients rather than merely buying time between relapses. Long-term follow-up from larger trials will be needed to determine how many of these responses endure indefinitely, but the trajectory of the phase 1 cohort provides the kind of early evidence that cellular therapy researchers look for when deciding whether a new construct deserves expansion into pivotal testing.

Equally important to the efficacy numbers was the safety picture, which distinguished anito-cel from earlier generations of BCMA-directed CAR-T therapies. Serious immune-related and neurological side effects were uncommon in the trial, and no delayed neurological complications were reported at all. That last point matters because some existing CAR-T cell therapies targeting BCMA have been linked to rare but serious neurological side effects, including delayed syndromes that can emerge weeks after infusion and cause lasting impairment. Patients with relapsed or refractory myeloma already endure substantial treatment burden, and the prospect of a therapy whose most feared complications appear to be largely absent represents a genuine shift in the risk-benefit calculation. The investigators reported that the absence of neurotoxic and inflammatory side effects was particularly encouraging given the serious and potentially lasting impact such complications can have on patients’ lives.

The apparent explanation lies in the molecular design of the construct itself. CAR-T therapy begins with a patient’s own T cells, which are extracted, genetically engineered to recognize a specific target on cancer cells, multiplied in the laboratory, and infused back into the patient. The recognition element, called the binding domain, determines both how effectively the engineered cells kill cancer and how vigorously they activate the immune system. Excessive activation drives the inflammatory toxicities that have shadowed CAR-T therapy since its inception, including cytokine release syndrome and neurotoxicity. According to the researchers’ laboratory analyses, anito-cel’s engineered BCMA-binding domain, described as a novel D-domain binder, maintained the cancer-killing activity required for efficacy while limiting the excessive immune activation and other features that can impair CAR-T cell function or contribute to toxicity. In other words, the design appears to have decoupled potency from inflammation, a goal that has eluded many previous construct engineering efforts.

Senior author Michael R. Bishop, MD, Professor of Medicine and Director of the David and Etta Jonas Center for Cellular Therapy at UChicago Medicine, framed the findings in the context of what phase 1 trials usually deliver. He described the results as great for a phase 1 study, noting that even at a low dose of anito-cel the team was seeing complete responses in the majority of patients right away, and that not a single patient developed severe toxicities. That combination, he said, prompted the investigators to investigate further why the safety profile was so favorable. Lead author Matthew Frigault, MD, vice chair of Clinical Research in Hematology/Oncology and deputy program director of the Cellular Immunotherapy Program at the Mass General Brigham Cancer Institute, highlighted the absence of neurotoxic and inflammatory side effects as particularly encouraging, and suggested that the novel D-domain binder may contribute to that finding. He added that the combination of compelling efficacy and encouraging safety data lays important groundwork for continuing to investigate this new treatment option for patients.

To understand why a BCMA-targeted therapy is so significant for myeloma specifically, it helps to consider the biology of the disease. BCMA, or B-cell maturation antigen, is a surface protein expressed on myeloma cells and largely restricted to the late B-cell lineage, which makes it an attractive bullseye: attacking it spares most healthy tissue while striking the malignant plasma cells directly. Two BCMA-directed CAR-T products are already approved for myeloma, and they have demonstrated that redirecting T cells against this target can produce deep remissions. The field’s outstanding questions concern durability, accessibility, and above all toxicity. The delayed neurological syndromes associated with some BCMA constructs, along with the cytokine-driven inflammatory storms that can accompany infusion, have constrained how these therapies are used and pushed clinicians to weigh carefully which patients should receive them. A construct that preserves efficacy while reducing these risks could widen the population for whom CAR-T therapy is a reasonable choice.

The trial itself was a phase 1 study, the first step in the clinical evaluation pathway, typically designed to establish dosing and identify side effects in a small cohort rather than to prove efficacy against a control group. That all 38 participants responded is not a randomized comparison, and phase 1 results by definition come with caveats about patient selection and cohort size. The investigators and the therapy’s developer, Kite, a Gilead company, have responded to the results in the standard way: anito-cel is currently being evaluated in phase 2 and phase 3 clinical trials intended to confirm the findings in larger populations of patients with multiple myeloma. Those pivotal studies will subject the construct to the scrutiny of broader enrollment, longer follow-up, and, in some designs, direct comparison against existing standards of care, which is the evidence regulators require before approving a new therapy.

The study also illustrates the growing sophistication of CAR-T engineering as a discipline. Early CAR-T constructs were largely borrowed from antibody fragments grafted onto T-cell signaling machinery, and the field learned through experience that the fine details of the binding domain, including its affinity, the geometry of its engagement with the target, and the signaling architecture it feeds into, profoundly shape the behavior of the resulting cells. The D-domain binder characterized in this trial reflects a deliberate design strategy: rather than accepting whatever toxicity profile a construct happens to produce, researchers are now engineering the recognition module itself to tune immune activation downward while preserving cytotoxic function. The laboratory analyses accompanying the clinical results, in which the researchers characterized the binder’s properties, point toward a future in which CAR-T products are designed with toxicity management built in at the molecular level rather than managed afterward with supportive drugs.

For patients and their physicians, the practical meaning of the trial is straightforward. Multiple myeloma remains incurable with current approaches, and treatment typically proceeds through a sequence of proteasome inhibitors, immunomodulatory drugs, antibody therapies, and eventually BCMA-directed options, each of which the disease may eventually evade. Anito-cel’s phase 1 data indicate that a next-generation BCMA CAR-T may deliver deep, durable remissions even in patients whose myeloma has already exhausted many prior therapies, with a safety profile that avoids the delayed neurological complications that have made some existing products difficult to deploy. The investigators caution that confirmation in larger trials is essential, and the ongoing phase 2 and phase 3 studies will determine whether the striking phase 1 experience holds up at scale. But the results, published in The New England Journal of Medicine under the title describing anito-cel as a D-domain BCMA CAR-T with phase 1 results and binder characterization, establish a credible new candidate in the cellular therapy pipeline for one of hematologic oncology’s most persistent challenges, and they demonstrate that rational engineering of the binding domain can translate into measurable clinical benefit at the bedside.

Subject of Research: A phase 1 trial of the BCMA-targeted CAR-T cell therapy anito-cel for relapsed or refractory multiple myeloma

Article Title: Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma

Article References: Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: multiple myeloma, CAR-T cell therapy, anito-cel, BCMA, phase 1 clinical trial, immunotherapy, D-domain binder, neurotoxicity, Mass General Brigham, University of Chicago Medicine, New England Journal of Medicine, relapsed refractory cancer

Retinitis pigmentosa is a group of inherited retinal degenerations that affects more than 1.5 million people worldwide. The disease progressively destroys the retina’s photoreceptors, the rods and cones that normally capture light and convert it into electrical signals for the brain. Patients typically first notice difficulty seeing at night, followed by a narrowing of peripheral vision that worsens over years, ultimately leading to severe vision loss or blindness. Because the retina is part of the central nervous system, its capacity for self-repair is extremely limited, and once photoreceptors are lost they are not naturally replaced.

One of the central obstacles to treating the disease is its sheer genetic diversity. Retinitis pigmentosa can arise from mutations in any one of more than 100 distinct genes, which makes a mutation-by-mutation strategy impractical for most patients. Gene therapies that correct specific defects have succeeded for other blinding conditions, but building and validating a separate treatment for every causative gene is proving tremendously difficult and costly. The Pittsburgh-led team, under the direction of José-Alain Sahel, chair of ophthalmology at Pitt and director of the UPMC Vision Institute, pursued a fundamentally different logic: rather than fixing the underlying mutation, the therapy aims to make surviving retinal cells light-sensitive again, regardless of which gene caused the degeneration.

The technical approach relies on optogenetics, in which cells are genetically altered to produce light-sensing proteins borrowed from other organisms. In this trial, the researchers delivered a gene encoding a protein called ChrimsonR into surviving retinal ganglion cells through a single injection into the eye. Retinal ganglion cells are the output neurons of the retina; in a healthy eye they relay signals from photoreceptors to the brain, and in advanced retinitis pigmentosa many of them remain viable even after the light-sensing cells above them have died. By equipping these surviving cells with an engineered light-sensitive protein, the therapy effectively converts the retina’s output neurons into a substitute photoreceptor layer.

ChrimsonR alone is not enough, however. The protein responds to specific wavelengths of amber-red light, and ordinary ambient illumination is not structured in a way the modified cells can interpret usefully. To bridge that gap, participants wear specialized goggles with a built-in camera that captures the visual scene and sends the information to a portable processor. The processor converts the image into patterns of light at wavelengths designed to activate ChrimsonR, and a projector inside the goggles projects those patterns back onto the retina. The system can, for example, transform the image of a hand into a simplified pattern of light that stimulates the treated cells, allowing the brain to receive visual information through a completely rewired pathway.

On safety, the early-stage trial delivered encouraging results. Most eye-related side effects were mild or moderate, consisting mainly of temporary inflammation and short-lived increases in pressure inside the eye. No findings reported in the release suggested the therapy itself caused lasting harm, an important benchmark for a treatment that involves permanently introducing a new light-sensing protein into neural tissue. The researchers emphasize that this was a small, early-stage study, and that the treatment did not restore normal vision or the ability to read. Even so, some participants became better able to detect when an object was present, determine where it was located, and reach toward it accurately while using the goggles, functional abilities that can translate into greater independence in daily life.

The study went beyond behavioral testing to ask whether the new visual signals were actually reaching the brain. Using electroencephalography, a team led by Marlene Behrmann, professor of ophthalmology at Pitt, found evidence that visual signals reached and were processed by the visual cortex when participants viewed objects. That finding is scientifically striking, because it suggests that in people with profound, long-standing vision loss, the brain’s visual processing machinery remains intact and capable of interpreting input delivered through an entirely novel channel. Four participants showed consistent improvements across multiple real-world visual tasks over months to years of testing, indicating that the gains were not fleeting artifacts of a single laboratory session.

Sahel noted that the results demonstrate the visual system retains a remarkable capacity to process new information even after profound vision loss. He also pointed to the approach’s broader potential: because the strategy targets surviving retinal ganglion cells rather than any specific mutation, it could in principle help patients with other blinding diseases in which light-sensing cells have been lost but ganglion cells remain viable, a group that currently has few or no treatment options. That mutation-agnostic design is what distinguishes optogenetic therapy from the growing but still narrow portfolio of gene-specific treatments.

The new findings build directly on a landmark 2021 study published in Nature Medicine, which reported the first partial recovery of visual function in a blind patient following optogenetic therapy, the first clinical application of optogenetics in medicine. That work, carried out with longtime collaborator Botond Roska of the Institute of Molecular and Clinical Ophthalmology Basel, who is also a corresponding author of the current study, earned the two researchers the António Champalimaud Vision Award, the largest prize in the field, last month. The current trial was conducted as part of the PIONEER clinical study with support from GenSight Biologics, and included collaborators from Sorbonne Université, Institut de la Vision, and L’Hôpital Fondation Adolphe de Rothschild in Paris, the Institute of Molecular and Clinical Ophthalmology Basel and University of Basel in Switzerland, Streetlab in Paris, and Moorfields Eye Hospital in London.

The optogenetic program is one of several complementary strategies the Pittsburgh-led team is pursuing for end-stage retinal disease. Last year, Sahel was senior author of a New England Journal of Medicine paper describing vision restoration using an implanted prosthetic device, known as PRIMA, in patients with end-stage age-related macular degeneration. That technology has since received European Union authorization to be marketed for clinical use in many European countries. Together, the two approaches illustrate a shifting landscape in which blindness once considered irreversible is being reclassified as a engineering problem: if light-sensing cells are gone, the task becomes finding surviving neural tissue that can be repurposed to carry visual signals, whether by genetically reprogramming ganglion cells or by implanting a photovoltaic prosthetic. For the retinitis pigmentosa community, the new trial offers the strongest evidence yet that such repurposing can work safely in humans, while underscoring how much work remains before the therapy could move from a small trial toward approved, widely available treatment.

Subject of Research: Optogenetic gene therapy for restoring visual function in advanced retinitis pigmentosa

Article Title: Optogenetic therapy safe, shows signs of vision restoration in patients with advanced retinitis pigmentosa, according to international study led by Pitt scientists

Article References: Optogenetic therapy safe, shows signs of vision restoration in patients with advanced retinitis pigmentosa, according to international study led by Pitt scientists. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: optogenetics, retinitis pigmentosa, gene therapy, retinal ganglion cells, ChrimsonR, visual prosthesis, New England Journal of Medicine, University of Pittsburgh, vision restoration, clinical trial, retinal degeneration, visual cortex

The significance of the achievement lies in the category of donors involved. REUP was originally developed by Vanderbilt’s adult heart transplant team for hearts donated after circulatory death, a category abbreviated as DCD. In DCD donation, the donor’s heart has already stopped beating before recovery begins, which distinguishes these organs from those retrieved after brain death, when the heart is still pumping at the time of procurement. Historically, recovering a heart that has ceased beating posed a fundamental problem: cardiac tissue deprived of blood flow begins to deteriorate rapidly, and the organ must somehow be revived or preserved before it can be transplanted into a recipient.

Existing approaches to DCD heart recovery have relied on reanimation. In one strategy, the donor’s circulation is restored in the body so the heart resumes beating before it is removed. In another, the heart is placed on a specialized ex situ perfusion machine that pumps blood or perfusate through it to restart its function outside the body. Both strategies can work, but each carries drawbacks. Reanimation inside the donor’s body raises ethical concerns in some settings, because it involves restoring circulation after death has been declared. Perfusion devices, meanwhile, can be expensive, technically complex, and constrained by the size of the patient, a limitation that is particularly consequential in pediatrics, where donor hearts may be as small as a walnut.

REUP takes a fundamentally different path. Rather than reanimating the donor heart, the technique preserves it by flushing the organ with a cold, oxygen-rich solution after death has occurred. The ultraoxygenated perfusate delivers oxygen to the myocardial tissue while the low temperature slows metabolism, allowing the heart to be maintained in a viable, non-beating state until transplantation. Because the heart is never restarted, the method sidesteps the ethical objections associated with in situ reanimation, and because it does not depend on bulky perfusion machinery sized to the patient, it can in principle be applied across the full range of donor sizes, from the smallest neonates to adolescents.

The pediatric adaptation of the technique is the heart of the new report. In the NEJM article, the team described five donor hearts recovered with REUP and transplanted into children ranging in age from just two days to fourteen years old. That span is itself notable: neonatal and infant hearts are among the most difficult organs to recover and transplant, and the demonstration that the technique works across all pediatric age groups suggests it could be applied broadly rather than being confined to a narrow subset of donors.

The outcomes reported in the study were striking. The five recipients waited an average of only twenty days for transplantation, a figure that stands in sharp contrast to the many months children often spend on the waiting list. No donor hearts were discarded during the recovery process, and every recipient demonstrated strong heart function after surgery. None of the children required mechanical circulatory support following transplantation, none experienced primary graft dysfunction, a feared early complication in which the transplanted heart fails to perform adequately, and none showed evidence of rejection during the study period. For a first-in-children application of a new preservation method, that combination of results represents an unusually clean safety and efficacy profile.

The clinical context helps explain why the Vanderbilt team describes the technique as transformative. More than 2,000 children are on the heart transplant waitlist in any given year, and waiting times can stretch across many months, particularly for neonates and infants, whose donor pool is the smallest and whose clinical deterioration while waiting is often the fastest. Long waits carry a grim toll: waitlist mortality among children awaiting heart transplantation is estimated at roughly twenty percent. In other words, one in five children on the list may die before a suitable organ becomes available. Any technique that reliably converts currently unusable donor hearts into transplantable ones attacks that mortality directly, and the Vanderbilt investigators noted that without REUP, the hearts in their study would not have been available for transplantation at all.

The ethical dimension of the work deserves particular emphasis. All of the donor recoveries included in the pediatric study took place in settings where donor heart reanimation was not permitted because of ethical concerns. This means the study population was drawn from precisely the circumstances in which DCD hearts are most often lost to transplantation: institutions and jurisdictions where the prevailing rules forbid restarting circulation in a donor after death. By demonstrating that hearts can be recovered and preserved without any reanimation step, REUP opens a pathway for those organs to be used in places where existing methods are simply off the table, potentially expanding the donor pool not only by making more hearts usable but by making them usable in more places.

The pediatric program’s success builds on a foundation of prior adult experience at Vanderbilt Health. Earlier studies from the adult heart transplant team showed that donor hearts could be safely recovered and preserved without reanimation before transplantation, findings that suggested the approach could make substantially more donor hearts available to patients in need. Aaron Williams, MD, Assistant Professor of Cardiac Surgery at Vanderbilt Health and first author of the NEJM article, noted that REUP has already helped expand the donor pool for adult heart transplantation, allowing the team to transplant more patients, recover hearts from greater distances, and achieve excellent outcomes. The ability to recover hearts across greater geographic distances is a quiet but important benefit of a preservation method that does not require the donor heart to be beating: organs can tolerate longer transport intervals when they are held in a cold, oxygenated, metabolically suppressed state.

Ziv Beckerman, MD, Associate Chief of Pediatric Cardiac Surgery and Surgical Director of Pediatric Heart Transplantation in the Golisano Pediatric Heart Institute at Monroe Carell and senior author of the article, described the approach as truly transformative for the field of pediatric heart transplantation, emphasizing that the ability to expand the organ donor pool and utilize hearts that would otherwise be discarded represents a genuine advance for patients. The team has stated its intention to help other transplant programs advance and adopt the technique, a dissemination effort that could determine how quickly the benefits reach the broader population of waiting children. If the early results hold up as the method spreads, a preservation strategy built on a simple idea, keeping a stopped heart cold and oxygenated rather than forcing it to beat, may become a standard tool in the effort to shorten wait times and save more young lives.

Subject of Research: Rapid recovery with extended ultraoxygenated preservation (REUP) of donor hearts donated after circulatory death for pediatric heart transplantation

Article Title: Monroe Carell Jr. Children’s Hospital at Vanderbilt leads breakthrough heart recovery method for pediatric transplants

Article References: Monroe Carell Jr. Children’s Hospital at Vanderbilt leads breakthrough heart recovery method for pediatric transplants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pediatric heart transplantation, REUP, donation after circulatory death, organ preservation, Vanderbilt, Monroe Carell Children's Hospital, New England Journal of Medicine, donor pool expansion, waitlist mortality, cardiac surgery, neonatal transplant, organ recovery

Khullar does not deny that clinical roles will change, or that some specific jobs may disappear as machines take over discrete tasks. His claim is subtler and, in some ways, more provocative: that the aggregate effect of AI on clinical employment is likely to be expansionary rather than contractionary. “But economic theory and history offer distinct reasons to believe that in the long run, adoption of AI agents—even models capable of performing some forms of cognitive work—could lead to an expansion, rather than a contraction, of the clinical workforce,” he wrote. The argument rests not on optimism about technology for its own sake, but on well-documented patterns in how efficiency gains reshape demand for human labor.

The first pillar of that argument is a phenomenon economists call Jevons paradox. In its original nineteenth-century formulation, the paradox described how improvements in the efficiency of coal use in Britain led to greater, not lesser, total coal consumption, because cheaper energy unlocked new uses across the economy. Khullar points to two surgical examples that illustrate the same dynamic in modern medicine: cataract surgery and joint replacement. Both procedures have become dramatically more efficient over recent decades, reducing the clinical effort required per operation, shortening recovery times, and improving safety. The result was not a shrinking demand for surgeons and operating room staff. Instead, as the procedures became faster, safer, and less burdensome for patients, far more people became candidates for them, and the total volume of care—and the workforce needed to deliver it—grew.

Khullar reasons that AI may exert a similar effect across other health care services, particularly if AI systems are priced near their marginal cost and thereby reduce the overall expense of delivering care. When the cost of a service falls, demand tends to rise, and health care is no exception. An AI-assisted diagnostic process that cuts the time a physician spends per case does not necessarily eliminate physician jobs; it can make each consultation cheaper and more accessible, drawing in patients who previously went unserved or underserved. In a country where millions of people lack adequate access to primary care, mental health services, and specialty evaluations, the latent demand for clinical attention is enormous. Efficiency, in this framing, is the mechanism by which unmet need becomes delivered care—and delivered care requires professionals.

The second pillar of the argument targets a persistent cognitive trap in workforce forecasting: the “lump of labor” fallacy. This is the mistaken assumption that there is a fixed quantity of work in an economy, so that any task performed by a machine must subtract from the pool available to humans. History repeatedly contradicts this view. The type and amount of work change over time in response to technological advances, and medicine is perhaps the clearest example. The discovery of antibiotics did not put physicians out of work; it created entire fields of infectious disease practice, intensive care, and public health. Imaging technologies did not eliminate doctors; they created radiology as a discipline and multiplied the conditions that could be identified and treated.

Khullar extends this logic to AI, arguing that the technology may allow clinicians to prevent or treat conditions in ways that are not currently possible or even imaginable. “AI may increase the demand for new professional capabilities by creating new treatments, care modes, and opportunities for specialization,” he wrote. If AI accelerates drug discovery, enables earlier detection of disease, or supports novel modes of remote and continuous care, each of those advances generates new clinical questions, new treatment pathways, and new roles for trained professionals to supervise, interpret, and integrate the technology into patient care. The workforce of an AI-rich health system may look different from today’s, but different does not mean smaller.

The third pillar addresses the granular structure of medical work itself. Delivering high-quality care involves far more than successfully executing a list of discrete tasks. The practice of medicine depends on numerous skills and many interconnected steps, from interpreting test results to developing and negotiating treatment plans with patients who have competing priorities, comorbidities, and preferences. Khullar invokes what economists call “O-ring theory,” a framework named for the faulty rubber seals that caused the Space Shuttle Challenger disaster. The theory holds that when production consists of many sequential steps, a single error at any step can seriously undermine the final outcome, and that the value of reliability at every stage rises accordingly.

That insight has particular force in health care, where many situations are high-stakes and the cost of a single catastrophic error is measured in lives, liability, and public trust. Even if an AI system performs individual cognitive tasks with superhuman accuracy, the chain of care that surrounds those tasks—verification, contextual judgment, communication, accountability, and the human relationship at the center of medicine—will continue to require clinicians, for reasons of both safety and trust. The practical implication is a distinction that Khullar emphasizes throughout the Perspective: automating tasks does not necessarily mean automating jobs. “In fact, if AI automates some clinical tasks, the value of nonautomated, human tasks may increase,” he said. As the routine components of a clinician’s day are handled by machines, the residual human components—those requiring empathy, negotiation, ethical judgment, and accountability—may become more valuable, not less.

The technical literature on automation in other industries offers a consistent picture of this dynamic. When automation decomposes a job, it typically reallocates human effort toward the tasks that machines handle worst: those involving ambiguity, dexterity, interpersonal connection, and responsibility for outcomes under uncertainty. In medicine, where the product is not a widget but a therapeutic relationship embedded in a complex biological and social context, the share of work that resists full automation is unusually large. An AI agent may draft a differential diagnosis or summarize a chart in seconds, but deciding how to present a terminal diagnosis, weighing whether an elderly patient with multiple conditions should undergo surgery, or earning the trust of a patient hesitant to accept treatment are tasks that remain stubbornly, and perhaps permanently, human.

None of this means the transition will be painless or evenly distributed. Khullar acknowledges that some types of health care jobs could be replaced, and clinicians in highly exposed specialties are right to scrutinize how their daily work maps onto what current AI systems can do. The composition of the workforce may shift, with new roles emerging around AI oversight, data quality, and hybrid human-machine care models, while some traditional task bundles are redefined. But the central claim of the Perspective is that the standard doom-laden forecast rests on flawed assumptions: that demand for care is fixed, that efficiency reduces total employment, and that a job is nothing more than the sum of its automatable parts. Economic theory and the historical record of medical technology suggest otherwise. If AI makes care cheaper, safer, and more capable, the United States may need more clinicians than ever—not to compete with the machines, but to do the human work the machines make possible.

Subject of Research: The potential impact of artificial intelligence on the future size and composition of the clinical workforce in the United States.

Article Title: How will AI impact the future of the clinical workforce?

Article References: How will AI impact the future of the clinical workforce?. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, clinical workforce, health policy, Jevons paradox, lump of labor fallacy, O-ring theory, New England Journal of Medicine, Weill Cornell Medicine, health care economics, medical automation, radiology, primary care

The therapy takes a fundamentally different approach from conventional gene replacement treatments. Retinitis pigmentosa is an inherited disease in which the retina’s light-sensing cells, the photoreceptors, gradually lose their ability to respond to light, and mutations in more than 100 different genes can cause the condition. Because the genetic causes are so varied, treatments directed at any single genetic defect can only help a small fraction of patients. Optogenetic therapy sidesteps that problem entirely: instead of repairing a broken gene, it gives surviving retinal ganglion cells a new job. These cells, which normally relay signals from photoreceptors to the brain, are genetically reprogrammed to become light-sensitive themselves, effectively converting them into a substitute photoreceptor layer even at very advanced stages of blindness.

In the trial, each participant received a single injection into their worse-seeing eye carrying the genetic instructions for ChrimsonR, a light-sensitive protein derived from microbial opsins that responds to amber light. ChrimsonR was chosen for its spectral properties, since amber light is less likely to cause phototoxic damage than shorter wavelengths and can penetrate ocular tissue relatively well. The genetic payload prompts the ganglion cells to produce the protein in their membranes, so that when amber light strikes them, they depolarize and fire signals upward through the visual pathways. But the engineered cells respond only to light levels far brighter than ordinary ambient illumination, which is where the second component of the system comes in.

That component is a pair of special goggles equipped with a camera. The goggles capture the visual scene in front of the wearer and convert changes in that scene into pulses of amber light projected onto the treated retina, delivering the intensity and contrast that ChrimsonR requires to activate. Put simply, the gene therapy makes surviving retinal cells sensitive to light, and the goggles provide the light signal those cells need. The combination transforms the goggles into an artificial photoreceptor interface: the camera does the work that dead photoreceptors once did, and the reprogrammed ganglion cells pass the information along to the brain in a form the visual system can begin to interpret.

Safety was the primary endpoint of the study, a critical question for any therapy involving an injection into an eye that still retains some residual function. Within the limits of the study, the treatment was considered safe. Most eye-related adverse events were mild or moderate, and one severe event occurred immediately after injection but resolved within minutes after treatment. That favorable safety profile, combined with evidence of benefit, removes one of the biggest obstacles standing between optogenetics and wider clinical application, since any therapy that permanently alters retinal cells must first demonstrate that it does not endanger the eye it is meant to help.

The efficacy results were equally significant. Seven of the ten patients became more sensitive to light after treatment, and six of them reached the predefined threshold for a clinically meaningful improvement. Among the eight patients who completed visual behavioural testing, four improved in tasks such as detecting or locating objects. Even more patients improved in ecologically meaningful activities: finding a doorway in a room, or following a line on the floor while wearing the goggles. These are precisely the kinds of visual abilities that determine whether a person with profound vision loss can navigate independently, orient themselves in unfamiliar spaces, and move through daily life with greater confidence.

Objective confirmation came from measurements of brain activity. Imaging showed signals consistent with visual information actually reaching the visual areas of the brain in treated patients, indicating that the signals generated by the reprogrammed ganglion cells and delivered through the goggles were not merely artifacts of retinal stimulation but were being transmitted and processed along the normal visual pathways. For a therapy that works by co-opting cells that were never designed to be photoreceptors, this demonstration that the brain can receive and register the new input is a crucial piece of evidence that the approach taps into the residual architecture of the visual system.

One of the study’s most instructive findings concerns the role of rehabilitation. Training played an important part in the outcomes: patients who spent more time learning to use the goggles tended to perform better on object-detection tests. That pattern suggests that the brain requires practice to interpret the unfamiliar, pixelated signal arriving from the engineered ganglion cells, and that rehabilitation may be an essential component of optogenetic therapy rather than an optional add-on. The implication for future clinical practice is that successful treatment will likely involve not just an injection and a device, but a structured program of visual training that helps patients learn to make sense of their new input.

The researchers are careful about what the therapy does and does not achieve. The treatment did not restore normal sight, and the patients still could not read or recognize faces. The visual experience produced by the system is far coarser than natural vision, constrained by the resolution of the goggles, the properties of ChrimsonR, and the density of surviving ganglion cells. Yet the significance of the results lies elsewhere: the study demonstrates that even at a very advanced stage of blindness, when photoreceptors are long gone, surviving retinal ganglion cells can be made responsive to light and can transmit visual information to the brain. That principle, now validated in a cohort rather than a single patient, opens a therapeutic window that did not previously exist for this population.

Stefan Futterknecht, second author of the study, who played a major role in analyzing the data, captured the significance of the moment: “This study represents an important milestone for optogenetic vision restoration. It demonstrates that the effects first observed in a single patient can be reproduced across several patients and provides a foundation for developing more sensitive and effective future therapies.” The full article, “Optogenetic Therapy for Restoring Aspects of Visual Function,” appeared in the New England Journal of Medicine. The same international collaboration that performed the 2021 proof-of-concept study carried out this work, and the consistency between the two results strengthens confidence that optogenetic vision restoration is a reproducible clinical reality. The path forward, the researchers indicate, lies in developing more sensitive and effective optogenetic proteins, refining the goggles, and optimizing training protocols, so that the partial sight demonstrated in this cohort can be deepened and extended to more of the people waiting for it.

Subject of Research: Optogenetic gene therapy with light-stimulating goggles for restoring visual function in blind patients with advanced retinitis pigmentosa

Article Title: Optogenetic therapy is safe and allows blind people to detect objects

Article References: Optogenetic therapy is safe and allows blind people to detect objects. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: optogenetics, retinitis pigmentosa, gene therapy, ChrimsonR, retinal ganglion cells, vision restoration, clinical trial, New England Journal of Medicine, IOB Basel, photoreceptors, visual rehabilitation, blindness

Estrogen-receptor-positive tumors account for roughly 70 percent of all breast cancers, making this the single largest subgroup of patients with metastatic disease. These tumors carry receptors that respond to the hormone estrogen, which acts as a growth signal, driving cancer cells to proliferate. For decades, the central strategy against them has been endocrine therapy, which blocks estrogen signaling in one way or another. But when the disease spreads beyond the breast, treatment becomes far more difficult, and resistance to hormonal agents eventually emerges in nearly every patient.

The landscape changed dramatically with the arrival of CDK4/6 inhibitors, drugs that shut down enzymes cancer cells rely on to progress through the cell division cycle. Combined with endocrine therapy, these agents greatly improved outcomes for patients with metastatic disease and became a global standard of care. Yet the benefit is not permanent. Once a tumor progresses through CDK4/6 inhibition, the options that remain are often limited, less effective, and associated with burdensome side effects. It is precisely this post-CDK4/6 setting that the evERA study was designed to target.

Giredestrant belongs to a class of drugs known as selective estrogen receptor degraders, or SERDs. Unlike conventional endocrine therapies that simply block the receptor, a SERD binds directly to the estrogen receptor and promotes its degradation, physically removing the molecular target that estrogen would otherwise activate. As a full antagonist, giredestrant not only eliminates the receptor but also blocks any residual activity. Because it is taken orally, it offers a convenient alternative to earlier injectable degraders such as fulvestrant, and its next-generation design aims to deliver more complete receptor suppression with a manageable safety profile.

The evERA trial paired giredestrant with everolimus, an inhibitor of mTOR, a protein kinase that sits downstream of growth-signaling pathways and that tumors frequently exploit to survive despite endocrine treatment. Everolimus is already approved in combination with endocrine therapy for this patient population, so the study asked a pointed question: does replacing the endocrine backbone with a superior receptor degrader improve results when the mTOR blockade is held constant? Notably, evERA was the first phase 3 study to compare a novel combination strategy head-to-head against a standard-of-care combination regimen in this setting, rather than testing a new drug alone against a single agent.

The trial enrolled 373 patients with ER-positive, HER2-negative advanced breast cancer, all of whom had previously received treatment. Participants were randomly assigned in a global, open-label design to receive either the oral combination of giredestrant plus everolimus or a standard-of-care endocrine therapy plus everolimus. Importantly, about 55 percent of the enrolled patients carried mutations in ESR1, the gene that encodes the estrogen receptor itself. These mutations, which commonly arise under the pressure of prior endocrine therapy, alter the receptor’s structure so that it becomes active even without estrogen, a classic mechanism of treatment resistance. The trial was powered to evaluate progression-free survival both in the overall intention-to-treat population and in the ESR1-mutated subgroup specifically.

The results in the ESR1-mutated subgroup were striking. With a median follow-up of 18.6 months, patients whose tumors harbored an ESR1 mutation and who received the giredestrant-containing regimen achieved a median progression-free survival of 10 months, compared with 5.5 months for those on the standard combination. That difference corresponds to a 63 percent reduction in the risk of disease progression or death, a near doubling of the time patients lived without their cancer advancing. In a disease setting where each additional month of control matters enormously to patients and clinicians alike, the magnitude of the effect stood out even to the investigators who designed the study.

The benefit extended across the entire trial population as well. In the intention-to-treat analysis, which included patients with and without ESR1 mutations, those treated with giredestrant plus everolimus reached a median progression-free survival of 8.8 months versus 5.5 months with the standard-of-care combination, translating to a 44 percent reduction in the risk of progression or death. The consistency of the signal across both the mutation-positive subgroup and the broader population suggests that the regimen’s advantage is not confined to a single molecular subset, although the effect was clearly most pronounced where ESR1 mutations had driven resistance.

Safety data offered reassurance that the efficacy gains did not come at an unacceptable cost. The safety profile of the giredestrant regimen was described as manageable and consistent with the known profiles of the individual study treatments, an important consideration given that everolimus is already associated with side effects such as mouth sores, fatigue, and metabolic changes that can complicate long-term use. Overall survival data from the study remain immature, meaning not enough time has passed for a definitive analysis, but the investigators reported that the trends are favorable, leaving open the possibility that the progression-free survival benefit may eventually translate into longer lives.

For the field, the evERA results signal a shift in how resistance to endocrine therapy might be tackled in metastatic breast cancer. By combining a degrader engineered to eliminate even mutated estrogen receptors with an agent that blocks a parallel survival pathway, the regimen attacks the disease through complementary mechanisms at once. Erica Mayer, Director of Breast Cancer Clinical Research at Dana-Farber Cancer Institute and principal investigator of the study, emphasized that there is an urgent need for more effective therapies for patients whose tumors develop resistance to current endocrine treatments and who have progressed after CDK4/6 inhibitors, and that the published results show a novel combination regimen can substantially improve disease control compared with a standard regimen, potentially benefiting a large number of patients with advanced breast cancer. The study was funded by F. Hoffmann-La Roche Ltd., and with the full publication in the New England Journal of Medicine, the giredestrant-everolimus combination now stands as one of the most consequential advances to date for patients facing metastatic hormone-receptor-positive disease.

Subject of Research: A phase 3 trial of giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer after CDK4/6 inhibitor therapy

Article Title: Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer

Article References: Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: giredestrant, everolimus, SERD, metastatic breast cancer, ER-positive, ESR1 mutation, progression-free survival, CDK4/6 inhibitors, endocrine therapy resistance, phase 3 trial, evERA study, New England Journal of Medicine